efinedbyavaccine-inducedantibody.Proc.NatlAcad.Sci.USA115,168–173 ticlevaccine.Biopharm.Int23Suppl10,26–34(20
018). 46. Fernandes,F.etal.Insectcellsasaproductionpl
utto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles.ExpertRev.Vaccines12,225–236(2013).
ccine:differentapproachesforonegoal.Virol.J.15,17(2018). 47. Influenza vaccine strategies for broad global acce
achbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_
ccine approach induces broad and long-lasting immunity in a randomized, 2021.
lacebo-controlledphaseItrial.Nat.Med.27,106–114(2021). 48. European Medicines Agency. Assessment report.
renstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.e
uction,distribution,supply,anddemand–whatitmeansfortheprovider.Am.J. assessment-report/supemtek-epar-public-assessment-
ed.121,S22–S27(2008). February2021.
lberbaum, R. S. The baculovirus expression vector system: a commercial 49. HealthCanada.RegisterofInnovativeDrugs[Upda
anufacturingplatformforviralvaccinesandgenetherapyvectors.Biotechnol.J. from https://www.canada.ca/en/health-canada/ser
0,702–714(2015). drug-products/applications-submissions/register-inn
ox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.
lls.J.Invertebr.Pathol.107,S31–S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin
aymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter.Proc.NatlAcad.Sci.USA95,9713–
g-adaptedvaccinestrain.Nat.Med.22,1465–1469(2016). 51. Stieneke-Gröber,A.etal.Influenzavirushemaggluti
owronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprote
ith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.
rculatingviruses.PLoSONE9,e92153(2014). 52. Chen,J.etal.Structureofthehemagglutininprec
ost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginof
ataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc. 95,409–417(1998).
atlAcad.Sci.USA114,12578–12583(2017). 53. Luczo,J.M.etal.MolecularpathogenesisofH5hi
annery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage sit
fectiveness-UnitedStates,February2017.MMWRMorb.Mortal.WklyRep.66, 406–430(2015).
7–171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated mem
u,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from perspective.AnnuRev.Biophys.47,153–173(2018).
siontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis- 55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Charact
bles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron micro
60-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms.Clin.Vaccin.Imm
ng,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculoviru
acterial expression: a solution to global pandemic and seasonal needs. PLoS insectandmammaliancells.Curr.Opin.Biotechnol.
NE3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Chang
ssey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeofH3influenzavirusatacid
asonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).
roteins.OpenForumInfect.Dis.3,ofw015(2016). 58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationof
guilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Micro
roducedinEscherichiacoli.PLoSONE5,e11694(2010). (2015).
czynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner,H.L.etal.Potentanti-influenzaH7human
acteria.ActaBiochimPol.61,561–572(2014). separation of hemagglutinin receptor-binding he
avis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).
pressedinEscherichiacoli.Gene21,273–284(1983). 60. Khurana,S.etal.Repeatvaccinationreducesantibo
osales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans.Na
ghtagainstCOVID-19?Vaccines8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highl
illet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope.Science324,246–251(2009).
duces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysi
munol.168,72–87(2016). allinfluenzaAsubtypes.Cell166,596–608(2016).
illet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a tr
eparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions
to49and>/=50yearsoldadults.PLoSONE14,e0216533(2019). 64. Portnoff,A.D.etal.Influenzahemagglutininnanop
ard,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad- neutralizingantibodiesagainststructurallydistinctd
valent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).
ults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards,K.A.etal.RecombinantHA-basedvaccin
91–1503(2020). unit vaccines in elicitation of influenza-specific C
on, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans.NPJVac
erived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingme
28–8038(2018). tionofinfluenzavirusvaccine.Hum.VaccinesImmun
andey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemaggl
ogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza virus and within vaccines using electron microsco
ccine.PLoSONE7,e33428–e33428(2012). 10.3390/vaccines6020031(2018).
yedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel- 68. PublicHealthAgencyofCanada.Oculo-respiratorys
pingthenextgenerationofinfluenzavaccines.Vaccines8,574(2020). vaccination:reviewofpost-marketing surveillance
iang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsinCanada.Can.Commun.Dis.Rep.31,217–22
um.VaccinImmunother.11,1209–1222(2015). 69. Choudhri,Y.&Walop,W.Influenzavaccine-associat
hen,J.R.etal.Betterinfluenzavaccines:anindustryperspective.J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Com
7,33(2020). (2002).
eport to the president on reengeneering the influenza vaccine production 70. Babiuk,S.etal.AggregatecontentinfluencestheT
terprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel.J.
bamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and20
fluenza-Vaccinology-Report.pdf.AccessedAugust2021. glycansinviralevolutionandvaccinedesign.Sci.T
pez-Macías,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influen
emic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneproce
ntrolledtrialofadultsinMexico.Vaccine29,7826–7834(2011). 10.1128/JVI.01693-18(2019).